Felecia Wagener

Fred Hutch Cancer Center — United States

Medicine · Health Sciences

11h-index1.3kcitations23works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(11), Immunotherapy and Immune Responses(8), Immune Cell Function and Interaction(5), Virus-based gene therapy research(4), Cancer Immunotherapy and Biomarkers(3)

Publications23 total

Targeting an alternate Wilms’ tumor antigen 1 peptide bypasses immunoproteasome dependency
Science Translational Medicine·2022· 37 citedOpen Access
T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant
Nature Medicine·2019· 310 citedOpen Access
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
Nature Communications·2018· 283 citedOpen Access
Abstract 2980: Single cell RNA sequencing reveals AML immunoediting under pressure from engineered T cell therapy
Cancer Research·2018
Single cell RNA sequencing reveals AML immunoediting under pressure from engineered T cell therapy
Oxford University Research Archive (ORA) (University of Oxford)·2018Open Access
A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia
Blood·2017· 60 citedOpen Access
Augmentation of adoptive T-cell therapy for Merkel cell carcinoma with avelumab.
Journal of Clinical Oncology·2017· 13 cited
Tracking the fate and origin of clinically relevant adoptively transferred CD8 <sup>+</sup> T cells in vivo
Science Immunology·2017· 60 citedOpen Access
P3.03-063 Phase 1/2 Trial of WT1 TCR-Transduced Central Memory and Naïve CD8+T Cells for Patients with Mesothelioma and Non-Small Cell Lung Cancer
Journal of Thoracic Oncology·2017
EBV-Specific Donor Cells Transduced to Express a High-Affinity WT1 TCR Can Prevent Recurrence in Post-HCT Patients with High-Risk AML
Blood·2016· 7 cited
T-Cell Therapy Using Interleukin-21–Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression
Journal of Clinical Oncology·2016· 114 citedOpen Access
Combined IL-21–primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient
The Journal of Experimental Medicine·2016· 82 citedOpen Access
Transferred Donor-Derived Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor Can Persist and Provide Anti-Leukemic Activity in AML Patients Post-Transplant
Blood·2014· 10 cited
Interleukin-21 Enhances Rituximab Activity in a Cynomolgus Monkey Model of B Cell Depletion and in Mouse B Cell Lymphoma Models
PLoS ONE·2013· 12 citedOpen Access
Abstract B71: Protective immunizations using cultured peripheral blood cells.
Cancer Research·2013
Abstract B18: Combining selective toll-like receptor 9 (TLR9) agonists and GM-CSF activity for potentiating cellular activation in active cell immunotherapy (ACI).
Cancer Research·2013
Anti-interleukin-21 monoclonal antibody reduces disease severity and inflammatory cytokines in a murine model of colitis and psoriasis-like skin inflammation
Cytokine·2009
Maintenance of interleukin-21 enhancement of T and NK cell effector function in the presence of dexamethasone
Journal of Clinical Oncology·2008
Diversity of the CD8<sup>+</sup>T-Cell Response to Herpes Simplex Virus Type 2 Proteins among Persons with Genital Herpes
Journal of Virology·2006· 102 citedOpen Access
Enhancement of trastuzumab-mediated cellular cytotoxicity by interleukin-21
Journal of Clinical Oncology·2005
page 1 of 2Next →

Frequent Co-authors

Aude G. Chapuis(13), Philip D. Greenberg(11), Thomas M. Schmitt(9), Daniel Hunter(7), Merav Bar(6), Megan S. McAfee(6), Kelly G. Paulson(6), Valentin Voillet(5), Raphaël Gottardo(5), Cecilia C.S. Yeung(5), Daniel Egan(4), Hieu Nguyen(4), Natalie Duerkopp(4), Maurizio Perdicchio(4), Cassian Yee(4), Jason H. Bielas(4), Shailender Bhatia(4), Kieu-Thu Bui(4), Cecile M. Krejsa(4), Petri R. Muhlhauser(3)